Unified Patents PTAB Data v. Omni Medsci Inc.

This case, Unified Patents PTAB Data v. Omni Medsci Inc., IPR2025-01583, involves a challenge to the patentability of U.S. Patent No. 9,651,533 before the Patent Trial and Appeal Board (PTAB). The petitioner, Unified Patents PTAB Data, is a member-based organization dedicated to deterring the assertion of low-quality patents by Non-Practicing Entities (NPEs) or "patent trolls" by filing inter partes reviews (IPRs). The patent owner, Omni Medsci Inc., is a patent assertion entity founded by Professor Mohammed N. Islam, which commercializes his optical technology and has a history of asserting its patents against major technology companies such as Apple, Samsung, Fossil, OnePlus, and Oura Health. While there is no "accused product" in an IPR, the underlying technology of the challenged patent generally pertains to medical device applications, specifically systems for measuring physiological parameters using wearable devices in conjunction with smartphones or tablets.

The patent at issue, U.S. Patent No. 9,651,533, broadly covers systems and methods for measuring physiological parameters, typically involving a wearable device and a connected smartphone or tablet. Notably, this patent has been previously subjected to IPR challenges, with some claims (5, 7-10, 13, and 15-17) having been canceled by the PTAB in a prior IPR initiated by Apple. The current proceeding's procedural posture is at the Patent Trial and Appeal Board, where the petition for IPR2025-01583 was ultimately "Not Instituted - Procedural." This status is particularly significant given recent shifts in PTAB practice, including increased discretionary denials under new USPTO policy changes implemented in 2025. These changes have granted the Director greater authority in determining whether to institute IPRs, often leading to petitions being denied on procedural grounds before a merits review.

This case is notable for several reasons. It highlights the ongoing efforts by Unified Patents to combat assertions by NPEs like Omni Medsci Inc., particularly in the evolving and commercially important field of wearable health technology. The "Not Instituted - Procedural" outcome underscores the challenging environment for IPR petitioners in 2025 and 2026, where stricter procedural hurdles and increased discretionary denials by the PTAB have led to a substantial decrease in IPR institution rates. This trend represents a significant shift in the landscape of patent validity challenges, potentially influencing strategies for both patent owners and challengers.

Key Legal Developments and Outcome for IPR2025-01583 and Related Litigation

This case involves an Inter Partes Review (IPR) proceeding, IPR2025-01583, before the Patent Trial and Appeal Board (PTAB), challenging U.S. Patent No. 9,651,533 owned by Omni Medsci Inc. While the prompt identifies "Unified Patents PTAB Data" as the plaintiff, official records indicate that WHOOP, Inc. filed the petition as the challenger, or petitioner, against Omni Medsci Inc. Unified Patents is likely involved in tracking or sponsoring the IPR. The IPR was not instituted on procedural grounds.

The patent at issue, US9651533, has also been involved in parallel patent infringement litigation in various U.S. District Courts.

IPR Proceeding: IPR2025-01583

• Filing & Initial Pleadings (IPR): On September 26, 2025, WHOOP, Inc. filed a petition for inter partes review, IPR2025-01583, challenging U.S. Patent No. 9,651,533. This IPR was part of a series of PTAB review proceedings initiated by WHOOP against Omni MedSci patents. The petition asserted grounds of invalidity for various claims of the '533 patent, primarily based on obviousness over prior art.

• Pre-Institution Phase & Outcome (IPR): The Patent Trial and Appeal Board decided not to institute an inter partes review for IPR2025-01583 on procedural grounds. The precise date and specific procedural reasoning for this decision are not publicly detailed in the available search results for this particular IPR. However, in 2025, the PTAB, under new leadership, implemented a stricter, policy-driven approach to IPR institution, which led to increased discretionary denials. This framework included a heightened focus on discretionary factors such as the Fintiv factors (considering parallel district court litigation timelines) and "settled expectations" for older patents. USPTO Director John A. Squires centralized control over all institution determinations in IPR and PGR cases, issuing summary notices for routine decisions without detailed explanations. Given the "Not Instituted - Procedural" status, the decision likely fell under these discretionary policies.

Parallel District Court Litigation and Other PTAB Proceedings

U.S. Patent No. 9,651,533 has been central to several patent infringement lawsuits, and other IPRs have been filed against it or related patents.

• 2018-2021: Omni MedSci, Inc. v. Apple Inc. (E.D. Tex. / N.D. Cal.)

  • Filing & Initial Pleadings: In 2018, Omni MedSci, Inc. sued Apple Inc. in the Eastern District of Texas (No. 2:18-cv-00134), asserting infringement of U.S. Patent Nos. 9,651,533 and 9,861,286.
  • Pre-trial Motions of Substance (Standing): Apple moved to dismiss for lack of standing, arguing that the University of Michigan (UM), not Omni MedSci, owned the asserted patents due to Dr. Islam's (the inventor's) employment agreement and UM bylaws. The District Court for the Eastern District of Texas denied Apple's motion, concluding that the UM bylaw was not a present automatic assignment of title. The case was subsequently transferred to the Northern District of California (e.g., No. 4:19-cv-05924 or 4:20-cv-00563). The California court certified the standing question for interlocutory appeal.
  • Appeal (Federal Circuit): On August 2, 2021, the Federal Circuit affirmed the district court's denial of Apple's motion to dismiss. The Federal Circuit held that the contractual language stating that patents "shall be the property of the University" was, at most, a statement of future intention to assign, and did not effectuate a present automatic assignment of patent rights to UM.
  • Other Pre-trial Motions (Summary Judgment): In July 2019, before the standing issue was fully resolved, Apple filed motions for partial summary judgment of invalidity of the '533 patent and non-infringement of certain claims, while Omni MedSci filed motions for partial summary judgment on patent subject matter eligibility and obviousness.

• 2019: Other IPRs against US9651533

  • Apple Inc. also filed IPR2019-00913 challenging the '533 patent. This petition was denied institution by the PTAB on October 16, 2019. This earlier denial highlights a history of the '533 patent successfully resisting PTAB challenges.

• 2024: Omni MedSci, Inc. v. Samsung Elecs. Co., Ltd. et al. (E.D. Tex., Case No. 2:24-cv-01070)

  • This is a related litigation where third parties, including Samsung, filed PTAB review proceedings against Omni MedSci's patents.

• 2025: Omni MedSci, Inc. v. WHOOP, Inc. (D. Del., Civil Action No. 25-140)

  • Filing & Initial Pleadings: Omni MedSci, Inc. filed this patent infringement lawsuit against WHOOP, Inc., asserting infringement of multiple patents, including U.S. Patent No. 9,651,533.
  • Pre-trial Motions of Substance (Motion to Stay): WHOOP, Inc. filed a motion to stay the district court case pending the resolution of various PTAB review proceedings, including IPR2025-01583. The district court initially denied a motion to stay in large part because the PTAB had not yet issued decisions on institution for all the petitions. However, a renewed motion to stay was conditionally granted after the PTAB instituted IPR, EPR, or PGR proceedings with respect to all the asserted claims in each of the asserted patents.

Effect of Parallel PTAB Proceedings on Litigation

The "Not Instituted - Procedural" outcome of IPR2025-01583 means that this specific IPR did not proceed to a substantive review of the patentability of the challenged claims. Consequently, it has a minimal direct effect on the district court litigation, as no final written decision on patentability was issued that could lead to estoppel. However, the filing of the IPR petition by WHOOP was a factor in the motion to stay the related district court litigation in Delaware. The broader trend of increased discretionary denials by the PTAB in 2025 has generally made it harder for petitioners to institute IPRs, potentially strengthening patent owners' positions in parallel litigation by reducing the likelihood of successful IPR challenges.

Unified Patents PTAB Data, as the petitioner in IPR2025-01583, typically leverages its in-house legal team for PTAB proceedings. While the specific counsel of record for IPR2025-01583 is not immediately apparent from general searches, Unified Patents frequently employs experienced patent attorneys as in-house Senior Patent Counsel to draft and litigate post-grant proceedings before the Patent Trial and Appeal Board.

Notable attorneys who have served in Senior Patent Counsel roles at Unified Patents and have extensive experience in PTAB litigation include:

• Jordan Rossen - Senior Patent Counsel, Unified Patents.

  • Firm: Unified Patents (in-house).
  • Office Location: Washington, DC (Unified Patents has a preference for candidates in this area, though remote work is possible).
  • Experience: Before joining Unified Patents, Rossen practiced in the intellectual property litigation departments at Ropes & Gray and Paul Hastings in Washington, DC for eleven years, representing clients before the PTAB, International Trade Commission, district courts, and the Federal Circuit. He has worked on cases across various industries including computer hardware and software, data processing, and medical devices.

• David Seastrunk - Senior Patent Counsel, Unified Patents.

  • Firm: Unified Patents (in-house).
  • Office Location: Washington, DC (preference for candidates in this area).
  • Experience: Prior to Unified Patents, Seastrunk practiced at Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, where he litigated all phases of post-grant proceedings, district court cases, and International Trade Commission investigations. He also has experience in patent prosecution and client counseling.

• Michelle Callaghan (now Michelle Aspen) - Senior Patent Counsel, Unified Patents.

  • Firm: Unified Patents (in-house).
  • Office Location: Washington, DC (preference for candidates in this area).
  • Experience: Before joining Unified Patents, Callaghan practiced at Erise IP, defending clients against patent demands in district courts, challenging patents before the PTAB, and preparing opinions on patent validity and infringement across various technologies including communication networks, video coding, and virtual reality.

While Unified Patents often uses its internal counsel for IPR filings, without direct access to the docket for IPR2025-01583, it is not possible to definitively name the specific attorney(s) who appeared for this particular, procedurally non-instituted case.

Omni Medsci Inc., as the Patent Owner (defendant in the context of defending its patent validity), in IPR2025-01583, likely engaged counsel specializing in patent litigation and Patent Trial and Appeal Board (PTAB) proceedings. While specific appearances for Omni Medsci Inc. in IPR2025-01583 are not extensively detailed in public search results, possibly due to its "Not Instituted - Procedural" status, their counsel in related patent infringement actions and other PTAB proceedings can be identified.

Based on related litigation, the following attorneys have represented Omni Medsci Inc.:

• William E. Davis, III
  • Role: Likely lead or co-lead counsel.
  • Firm: Davis Firm PC, Longview, Texas.
  • Experience Note: Represents Omni Medsci Inc. as plaintiff in district court patent infringement cases involving patents, including U.S. Patent No. 9,651,533, which is at issue in IPR2025-01583.
• Ty Wilson
  • Role: Likely co-lead counsel or associate.
  • Firm: The Davis Firm, PC, Longview, Texas.
  • Experience Note: Also represents Omni Medsci Inc. in district court patent infringement lawsuits, similar to William E. Davis, III.
• William E. Thomson, Jr.
  • Role: Counsel.
  • Firm: Brooks Kushman P.C.
  • Experience Note: Certified as counsel for Omni Medsci, Inc. in a case before the United States Court of Appeals for the Federal Circuit, indicating involvement in Omni Medsci's patent litigation at various levels.
• John M. Halan
  • Role: Counsel.
  • Firm: Brooks Kushman P.C.
  • Experience Note: Also certified as counsel for Omni Medsci, Inc. in a case before the United States Court of Appeals for the Federal Circuit, suggesting involvement in their appellate patent matters.

It is important to note that IPR2025-01583 was "Not Instituted - Procedural." Therefore, a detailed record of counsel's arguments or substantive filings on behalf of Omni Medsci Inc. for this specific IPR is not readily available. The attorneys listed above are identified through their representation of Omni Medsci Inc. in broader patent litigation involving the same patent or related matters, making them likely candidates to handle the IPR defense for the patent owner.